The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Addition of bevacizumab to compensate for the negative influence of attenuated relative dose intensity of cytotoxic agents on the outcome in patients with metastatic colorectal cancer.
Goro Nakayama
No relevant relationships to disclose
Naomi Hayashi
No relevant relationships to disclose
Chie Tanaka
No relevant relationships to disclose
Tsutomu Fujii
No relevant relationships to disclose
Yuichi Ando
No relevant relationships to disclose
Yasuhiro Kodera
No relevant relationships to disclose